First Analysis upgraded shares of Catalent (NYSE:CTLT) from a neutral rating to an outperform rating in a research report report published on Wednesday morning, Marketbeat.com reports. They currently have $43.00 target price on the stock, down from their previous target price of $47.00.
A number of other research analysts have also weighed in on CTLT. Zacks Investment Research lowered shares of Catalent from a buy rating to a hold rating in a research report on Thursday, July 26th. JPMorgan Chase & Co. boosted their target price on shares of Catalent from $50.00 to $55.00 and gave the stock an overweight rating in a research report on Wednesday, August 29th. UBS Group initiated coverage on shares of Catalent in a research report on Tuesday, October 9th. They set a neutral rating and a $48.00 target price for the company. Finally, ValuEngine lowered shares of Catalent from a buy rating to a hold rating in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Catalent currently has a consensus rating of Buy and an average target price of $48.11.
Catalent stock traded down $0.14 on Wednesday, reaching $37.51. 1,133,400 shares of the stock were exchanged, compared to its average volume of 857,435. The firm has a market cap of $5.48 billion, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.24 and a beta of 1.45. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.79. Catalent has a twelve month low of $34.24 and a twelve month high of $47.87.
In other news, SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total transaction of $277,312.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Barry Littlejohns sold 47,265 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $41.64, for a total transaction of $1,968,114.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 184,335 shares of company stock worth $8,161,727. Insiders own 1.40% of the company’s stock.
Several large investors have recently bought and sold shares of CTLT. BlackRock Inc. increased its stake in Catalent by 7.0% in the third quarter. BlackRock Inc. now owns 12,628,951 shares of the company’s stock valued at $575,248,000 after acquiring an additional 822,258 shares during the period. JPMorgan Chase & Co. increased its stake in Catalent by 29.5% in the third quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after acquiring an additional 1,819,020 shares during the period. Janus Henderson Group PLC increased its stake in Catalent by 13.0% in the third quarter. Janus Henderson Group PLC now owns 7,234,661 shares of the company’s stock valued at $329,539,000 after acquiring an additional 833,924 shares during the period. FMR LLC increased its stake in Catalent by 1.5% in the second quarter. FMR LLC now owns 3,781,793 shares of the company’s stock valued at $158,420,000 after acquiring an additional 54,678 shares during the period. Finally, American Century Companies Inc. increased its stake in Catalent by 6.4% in the second quarter. American Century Companies Inc. now owns 3,052,515 shares of the company’s stock valued at $127,870,000 after acquiring an additional 183,880 shares during the period. Institutional investors own 92.08% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: S&P 500 Index
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.